STAT1 and Miyoshi myopathy: Several medications used to treat patients with MM, including IMiDs (lenalidomide-LEN and pomalidomide-POM), and histone deacetylase (HDAC) inhibitor, panobinostat (PANO), activate the phosphorylation of STAT1, resulting in the transcription of IFN-γ target genes [20–22].